1921
Volume 71, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The efficacy of amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP) was assessed in 310 symptomatic children from western Kenya with uncomplicated malaria. A non-blinded, randomized, 14-day study was performed and parasitologic criteria were used. Of 310 patients included, 238 (77%) completed the study: 120 received AQ and 118 received SP. In those treated with AQ, there were sensitive (S) infections in 107 patients (89.2%, 95% confidence interval [CI] = 82.2, 94.1%), RI resistance in 10 (8.3%, 95% CI = 4.1, 14.8%), RII resistance in 1 (0.8%, 95% CI = 0, 4.6%), and RIII resistance in 2 (1.7%, 95% CI = 0.2, 5.9%). In those treated with SP, there were S infections in 74 patients (62.7%, 95% CI = 53.3, 71.4%), RI resistance in 21 (17.8%, 95% CI = 11.4, 25.9%), RII resistance in 11 (9.3%, 95% CI = 4.7, 16.1%), and RIII resistance in 12 (10.2%, 95% CI = 5.4, 17.1%). Resistance rates were consistently higher in the SP-treated patients ( < 0.001). Resistance to SP in this area has reached such levels that it should no longer be the first-line treatment. Alternative treatment, such as SP plus AQ combination treatment or artemisinin combination treatment, is urgently needed.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2004.71.537
2004-11-01
2017-11-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/71/5/0700537.html?itemId=/content/journals/10.4269/ajtmh.2004.71.537&mimeType=html&fmt=ahah

References

  1. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 : 1965–1967.
  2. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F, 1998. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 321 : 689–697.
  3. Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 87 : 75–78.
  4. van Dillen J, Custers M, Wensink A, Wouters B, van Voorthuizen T, Voorn W, Khan B, Muller L, Nevill C, 1999. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 93 : 185–188.
  5. East African Network for Monitoring Antimalarial Treatment, 2003. The efficacy of antimalarial montherapies, sulphadoxine-pyrimethamine and amodiaquine in east Africa: implications for sub-regional policy. Trop Med Int Health 8 : 860–867.
  6. Ronn AM, Msangenu HA, Mhina J, Wersdorfer WH, Bygbjerg IC, 1996. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 90 : 179–181.
  7. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, Msokame C, Aponte JJ, Tanner M, Mshinda H, Menendez C, Alonso PL, 2002. The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67 : 17–23.
  8. White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 30 : 571–585.
  9. Shretta R, Omumbo J, Rapuoda B, Snow RW, 2000. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 5 : 755–764.
  10. Nguyen-Dinh P, Spencer HC, Chenabgey-Masaba S, Churchill FC, 1982. Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya. Lancet i : 823–825.
  11. Spencer HC, Watkins WM, Sixsmith DG, Koech DK, 1986. Response of Plasmodium falciparum to dihydrofolate reductase inhibitors in Malindi, Kenya. Trans R Soc Trop Med Hyg 80 : 201–203.
  12. Keuter M, van Eijk A, Hoogstrate M, Raasveld M, van de Ree M, Ngwawe WA, Watkins WM, Were JBO, Brandling-Bennett AD, 1990. Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega district, Kenya. BMJ 301 : 466–470.
  13. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC, 1993. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 167 : 932–937.
  14. Hagos B, Khan B, Ofulla AVO, Kariuki D, Martin SK, 1993. Response of falciparum malaria to chloroquine and three second line antimalarial drugs in Kenyan coastal school age population. East Afr Med J 70 : 620–623.
  15. Anabwani GM, Esamai FO, Menya DA, 1996. A randomised contolled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine, and Fansidar® in the treatment of uncomplicated malaria in children. East Afr Med J 73 : 155–158.
  16. Clarke D, Odialla H, Ouma J, Kenny V, MacCabe R, Rapuoda B, Watkins WM, 1996. A malariometric survey in Turkana District, Kenya: chemosensitivity in vivo of Plasmodium falciparum infections and identity of the vector. Trans R Soc Trop Med Hyg 90 : 302–304.
  17. Gorissen E, Ashruf G, Lamboo M, Bennebroek J, Gikunda S, Mbaruku G, Kager PA, 2000. In vivo efficacy study of amodi-aquine and sulfadoxine/pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Trop Med Int Health 5 : 459–463.
  18. Bousema JT, Gouagna LC, Meutstege AM, Okech BE, Akim NI, Githure JI, Beier JC, Sauerwein RW, 2003. Treament failure of pyrimethamine-sulfadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Trop Med Int Health 8 : 427–430.
  19. Ogutu BR, Smoak BL, Nduati RW, Mbori-Ngacha DA, Mwathe F, Shanks GD, 2000. The efficacy of pyrimethamine-sulfadoxine (Fansidar®) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. Trans R Soc Trop Med Hyg 94 : 83–84.
  20. Mberu EK, Mosobo MK, Nzila AM, Kokwaro GO, Sibley CH, Watkins WM, 2000. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am J Trop Med Hyg 62 : 396–401.
  21. Olliaro P, Nevill C, Le Bras J, Ringwald P, Mussano P, Garner P, Brasseur P, 1996. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348 : 1196–1201.
  22. Adjuik M, Agnamey P, Babiker A, Borrmann S, Prasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui P-B, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WRJ, 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet 359 : 1365–1372.
  23. Keuter M, Sanders J, Ronday M, Veltkamp S, Kamsteeg H, Schouten E, Khalumi G, Ngwawe W, Wetsteyn JC, Brandling-Bennett AD, 1992. Parasitological, clinical and haematological response of children with Plasmodium falciparum to 4-amino-quinolines and to pyrimethamine-sulfadoxine with quinine in western Kenya. Trop Geogr Med 44 : 1–8.
  24. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ, 2001. Amodiaquine, sulfadoxine/ pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358 : 368–374.
  25. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, Kamya MR, 2003. Comparative efficacy of ami-noquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 68 : 127–132.
  26. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, Hills E, Watkins W, 2001. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358 : 1218–1223. Erratum in Lancet 358: 1556.
  27. Anonymous, 1973. Chemotherapy of malaria and resistance to antimalarials. World Health Organ Tech Rep Ser 529.
  28. Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, Coulibaly D, Thera M, Wellems TE, Diallo DA, 2001. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 64 : 242–247.
  29. Siringi S, 2001. Over-the-counter sale of antimalaria drugs stalls Kenyan disease strategy. Lancet 357 : 1862.
  30. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV, 2001. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358 : 1066–1067.
  31. Khalil I, Rønn AM, Alifrangis M, Gabar HA, Satti GMH, Bygbjerg IBC, 2003. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg 68 : 586–589.
  32. Terlouw DJ, Courval JM, Kolczak MS, Rosenberg OS, Oloo AJ, Kager PA, Lal AA, Nahlen BL, ter Kuile FO, 2003. Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in western Kenya. J Infect Dis 187 : 467–476.
  33. Terlouw DJ, Nahlen BL, Courval JM, Kariuki SK, Rosenberg OS, Oloo AJ, Kolczak MS, Hawley WA, Lal AA, ter Kuile FO, 2003. Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. Antimicrob Agents Chemother 47 : 2929–2932.
  34. International Artemisinin Study group, 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363 : 9–17.
  35. McIntosh HM, 2001. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria, Cochrane Database Syst Rev 2001: 4:CD000386.
  36. Rwagacondo CE, Niyitegeka F, Sarushi J, Karema C, Mugisha V, Dujardin JC, Van Overmeir C, van den Ende J, D’Alessandro U, 2003. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine-pyrimethamine combined with artesunate. Am J Trop Med Hyg 68 : 743–747.
  37. Hien TT, Dolecek C, Mai PP, Dung NT, Truong NT, Thai le H, An DT, Thanh TT, Stepniewska K, White PN, Farrar J, 2004. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 363 : 18–22.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2004.71.537
Loading
/content/journals/10.4269/ajtmh.2004.71.537
Loading

Data & Media loading...

  • Received : 02 Jul 2003
  • Accepted : 28 May 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error